AI and quantum science power new personalized brain cancer vaccine trial
NCT ID NCT07077616
Summary
This early-phase trial is testing a personalized vaccine designed to treat glioma, a type of brain cancer. The vaccine is custom-made for each patient using their unique tumor profile, artificial intelligence (AI), and quantum mechanics models. The goal is to train the patient's own immune system to recognize and attack their cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biogenea Pharmaceuticals Ltd
RECRUITINGThessaloniki, 54627, Greece
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.